News

Bristol Myers Squibb: Why I'm Pounding The Table On This Buying Opportunity
Bristol Myers Squibb offers a 5.6% dividend yield, strong cash flow, and AI-driven growth potential. See why I see this as a ...
PMLive12m
BMS and Bain Capital launch new company to develop immunology therapies
Bristol Myers Squibb (BMS) and Bain Capital have created an independent biopharmaceutical company to develop immunology ...